<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117763</url>
  </required_header>
  <id_info>
    <org_study_id>99613518.9.0000.0068</org_study_id>
    <nct_id>NCT04117763</nct_id>
  </id_info>
  <brief_title>Effect of Empagliflozin on Ventricular Repolarization.</brief_title>
  <acronym>EMPATHYHEART</acronym>
  <official_title>Effect of EMPAgliflozin on The HeterogeneitY of Ventricular Repolarization in Patients With Diabetes and Coronary HEART Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project aims to investigate if the empagliflozin has an antiarrhythmic action.&#xD;
      Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated&#xD;
      with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease,&#xD;
      the investigators will verify if empagliflozin is associated with a reduction in electrical&#xD;
      instability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular diseases are the leading cause of morbidity and mortality in diabetic&#xD;
      patients.&#xD;
&#xD;
      New hypoglycemic drugs are required to undergo cardiovascular safety studies for their&#xD;
      release. In 2015, EMPA-REG OUTCOME, which was done for empagliflozin´s approval was the first&#xD;
      study to provide evidence that an antidiabetic agent could decrease cardiovascular events.&#xD;
      The results demonstrated a reduction in the primary outcome (death by cardiovascular causes,&#xD;
      nonfatal infarction, and nonfatal stroke), cardiovascular mortality and hospitalization for&#xD;
      heart failure in patients with type 2 diabetes at high cardiovascular risk who received&#xD;
      empagliflozin in combination with standard treatment. It is noteworthy that the study&#xD;
      population was under-optimized clinical treatment with antihypertensives, statin and aspirin&#xD;
      and especially it is noteworthy that the difference in the primary outcome over placebo&#xD;
      became evident only three months after treatment´s start.&#xD;
&#xD;
      The potential mechanisms underlying the surprising cardiovascular benefits of empagliflozin&#xD;
      are not fully understood.&#xD;
&#xD;
      The present project aims to investigate if the empagliflozin has an antiarrhythmic action.&#xD;
      Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated&#xD;
      with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease,&#xD;
      we will verify if empagliflozin is associated with a reduction in electrical instability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patient data will be compared before and after treatment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmogenic burden</measure>
    <time_frame>3 months</time_frame>
    <description>Analysis of the T-wave heterogeneity index</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Arrythmia, Cardiac</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin 25 mg once daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>Empagliflozin once daily, for three months</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age ≥ 18 years;&#xD;
&#xD;
               -  Fasting glycemia&gt; 100 mg/dl or previous diagnosis of type 2 diabetes mellitus;&#xD;
&#xD;
               -  Coronary artery disease, defined by one of the following criteria: the antecedent&#xD;
                  of myocardial infarction; the evidence of significant coronary stenosis in&#xD;
                  previous coronary angiography; the noninvasive positive test for ischemia (stress&#xD;
                  electrocardiogram, stress echocardiogram, stress scintigraphy)&#xD;
&#xD;
               -  TWH ≥ 80 microvolts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic renal insufficiency with glomerular filtration rate ≤ 45 ml / min / 1.73m2;&#xD;
&#xD;
          -  Hepatic insufficiency (determined by Child-Pugh, B or C classification);&#xD;
&#xD;
          -  Age ≥ 85 years;&#xD;
&#xD;
          -  12-lead resting electrocardiogram with the following changes: intraventricular&#xD;
             conduction disorders (bundle branch block), pacemaker rhythm, atrial fibrillation or&#xD;
             flutter, artifact stroke distortion or baseline fluctuation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Caramelli, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Caramelli, MD, PhD</last_name>
    <phone>+5511984570650</phone>
    <email>bcaramel@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristiane Lauretti, MD</last_name>
    <phone>+5511986399660</phone>
    <email>crislauretti@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>InCor</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Caramelli, MD, PhD</last_name>
      <phone>11984570650</phone>
      <email>bcaramel@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Cristiane Lauretti, MD</last_name>
      <phone>+5511986399660</phone>
      <email>crislauretti@usp.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Bruno Caramelli</investigator_full_name>
    <investigator_title>Associated Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>empagliflozin</keyword>
  <keyword>Diabetes</keyword>
  <keyword>coronary heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

